600and1
Category: AI in Biotech / Drug Discovery
A biotechnology startup and AI-powered incubator dedicated to bioengineering human lifespan extension and decoding consciousness through the intersection of neuroscience and mitochondrial research. 600and1 was founded in 2025. The company is led by Berenika Maciejewicz. Based in San Francisco, USA. Team size: 10-50. Total funding raised: Undisclosed. Latest round: Venture Round.
- Founded
- 2025
- Headquarters
- San Francisco, USA
- Team size
- 10-50
- Total funding
- Undisclosed
Value proposition
Accelerates the discovery of longevity breakthroughs by combining AI-driven data analysis with novel neuroscientific frameworks to target the biological roots of aging and consciousness.
Products and solutions
AI-Powered Longevity Incubator (supporting biotech startups in the aging space), 600and1 Research Fund (focused on decoding and bioengineering aging), Mitochondrial-targeting therapeutic interventions, Cognitive neuroscience framework for conscious/lucid dreaming research, Proprietary reality-check induction protocols for consciousness exploration
Unique value
The company utilizes a highly unconventional approach by linking lucid dreaming and cognitive neuroscience to bioengineering, treating consciousness as a programmable variable in the human lifespan equation.
Target customer
Biotech researchers, longevity-focused investors, healthcare institutions, and individuals seeking advanced anti-aging and cognitive enhancement interventions.
Industries served
Biotechnology, Healthcare AI, Longevity & Anti-Aging, Neuroscience, Venture Capital (Incubation)
Technology advantage
Leverages the 'Triple Doctor' expertise of founder Dr. Berenika Maciejewicz to bridge MD-level clinical practice, PhD-level neuroscience, and PhD-level biomedical engineering with AI-driven drug and intervention discovery.
How they differentiate
Integrates cognitive neuroscience and lucid dreaming research with mitochondrial-targeting interventions, operating both as a research entity and an AI-powered incubator.
Main competitors
Altos Labs, Retro Biosciences, NewLimit
Key partnerships
DREAM 500 LLC (Executive leadership and research synergy), London Metropolitan University (Academic research affiliation), Web Summit (Strategic platform for Medtech and Longevity advocacy), Einstein Medical Institute (Research and educational collaboration)
Notable customers
Biotech startups within its AI-powered incubator
Major milestones
Official launch of the 600and1 Research Fund (January 2025), Launch of the AI-Powered Longevity Incubator to support aging-focused startups (January 2025), Attained Unicorn valuation status (January 2025), Founder Dr. Berenika Maciejewicz featured as a speaker at Web Summit 2025
Growth metrics
Achieved self-reported 'Unicorn' status ($1B+ valuation) upon public launch in early 2025.
Market positioning
High-valuation longevity biotech and venture incubator focusing on the intersection of consciousness and bioengineering.
Geographic focus
North America (HQ: San Francisco), Global research initiatives
Patents and IP
No specific registered patent numbers disclosed; however, the company claims proprietary IP regarding 'novel reality check induction protocols' and mitochondrial-targeting methodologies.
About Berenika Maciejewicz
Dr. Berenika Maciejewicz is a 'triple doctor' with an MD and two PhDs (Neuroscience and Biomedical Engineering). She transitioned from a successful career as a film producer (2012-2014), where she produced over 10 internationally distributed titles and won three Prestige Gold Awards, to becoming a leading longevity scientist. Her research focuses on the cognitive neuroscience of consciousness and lucid dreaming, which she applies to bioengineering human lifespan extension.
Official website: https://600and1.com